Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Gaby Zeck"'
Autor:
Radwan Massoud, Nico Gagelmann, Ulrike Fritzsche-Friedland, Gaby Zeck, Silke Heidenreich, Christine Wolschke, Francis Ayuk, Maximilian Christopeit, Nicolaus Kröger
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. Data comparing immune reconstitution (IR) between
Externí odkaz:
https://doaj.org/article/974a841e64fc4c5c8a28d5d27839a385
Autor:
Christine Wolschke, Gaby Zeck, Maximilian Christopeit, Francis Ayuk, Nicolaus Kröger, Isik Kaygusuz Atagunduz
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:2279-2284
In this cross-sectional study, we retrospectively evaluated the files of 227 patients with myelofibrosis who underwent transplantation between 1994 and 2015 for relapse later than 5 years after allogeneic stem cell transplantation (SCT). A total of 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ecef6960ce91d3b7314ba33a0fdcf52
https://doi.org/10.1016/j.bbmt.2020.09.006
https://doi.org/10.1016/j.bbmt.2020.09.006
Autor:
Ulrike Fritzsche-Friedland, Silke Heidenreich, Francis Ayuk, Nico Gagelmann, Nicolaus Kröger, Radwan Massoud, Gaby Zeck, Maximilian Christopeit, Christine Wolschke
Publikováno v:
Haematologica. 107(4)
Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. Data comparing immune reconstitution (IR) between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e3bfe7eaf31b1f18e6c450b93df936
https://pubmed.ncbi.nlm.nih.gov/33832208
https://pubmed.ncbi.nlm.nih.gov/33832208
Autor:
Christine Wolschke, Francis Ayuk, Ute-Marie von Pein, Nicolaus Kröger, Maximilian Christopeit, Giulia Daghia, Tatjana Zabelina, Gaby Zeck
Publikováno v:
European journal of haematologyREFERENCES. 103(4)
Introduction Myelofibrosis (MF) is a disease of elderly with median age of 65 years at diagnosis. Allogeneic stem cell transplantation (ASCT) currently is the only potentially curative option, although associated with treatment-related morbidity and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9763df057641eaa29f4bb63b622f67f9
https://pubmed.ncbi.nlm.nih.gov/31306511
https://pubmed.ncbi.nlm.nih.gov/31306511
Autor:
Maximilian Christopeit, Anita Badbaran, Gaby Zeck, Christine Wolschke, Tatjana Zabelina, Boris Fehse, N Kröger, F Ayuk
Publikováno v:
Bone Marrow Transplantation. 51:1391-1393
Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d1941f7553e17f48b9ad6d3023b227
https://doi.org/10.1038/bmt.2016.128
https://doi.org/10.1038/bmt.2016.128
Autor:
Daniele Mannina, Tatjana Zabelina, Nicolaus Kroeger, Francis Ayuk, Gaby Zeck, Ute-Marie von Pein, Christine Wolschke
Publikováno v:
Blood. 132:5783-5783
INTRODUCTION Allogeneic stem cell transplantation (alloSCT) is the only curative procedure for primary and secondary myelofibrosis (PMF, SMF). Elderly people are mainly affected, limiting the feasibility of intensive myeloablative chemotherapy regime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b5c8040f75613f09e320bbf10c9a377
https://doi.org/10.1182/blood-2018-99-112137
https://doi.org/10.1182/blood-2018-99-112137
Autor:
Tatjana Zabelina, Francis Ayuk, Ute-Marie von Pein, Christine Wolschke, Nicolaus Kroeger, Gaby Zeck, Giulia Daghia, Maximilian Christopeit
Publikováno v:
Blood. 132:4637-4637
Introduction Myelofibrosis (MF) is predominantly a disease of the elderly with a median age of 65 years at diagnosis. Allogeneic stem cell transplantation (ASCT), which is associated with substantial treatment-related morbidity and mortality, is the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::887970ee14769969079ac214df564110
https://doi.org/10.1182/blood-2018-99-113255
https://doi.org/10.1182/blood-2018-99-113255
Autor:
Christine Wolschke, Gaby Zeck, Francis Ayuk, Anita Badbaran, Maximilian Christopeit, Malik Alawi, Nicolaus Kröger, Tatjana Zabelina
Publikováno v:
European journal of haematology. 97(3)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for myelodysplastic syndromes (MDS). Little is known about the prognostic impact of mutations, for example, in TP53 specifically after allo-HSCT. We here de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10c48d0edeefc08c2056c45c640b261d
https://pubmed.ncbi.nlm.nih.gov/26680262
https://pubmed.ncbi.nlm.nih.gov/26680262